HIGHLIGHTS
- who: Anne Dierks and collaborators from the Department of Cell Physiology and Biophysics, Institute of Cell Biology and Biophysics, Leibniz University Hannover, Hannover, Germany have published the research work: The Bioactive Phenolic Agents Diaryl Ether CVB2-61 and Diarylheptanoid CVB4-57 as Connexin Hemichannel Blockers, in the Journal: Pharmaceuticals 2022, 1173 of /2022/
- what: The authors report the study of CVB2-61, a phenolic diarylether, which is a dimer of a vanillin derivate with antiatherogenic properties and CVB4-57, a diarylheptanoid and a curcuminoid analogue, as specific agents to target Cx hemichannels. This study shows . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.